心血管

订阅

MedSci主页 / 所有栏目 / 心血管

心血管回顾性研究采用MACE作为结局哪些地方会被挑战 ?

2021-07-29 MedSci原创 MedSci原创

药物流行病学心血管回顾性研究
关注

心血管回顾性研究采用mace作为结局哪些地方会被挑战-第十二个问题.

《梅斯直播课：药物流行病学——打开药物疗效和应用安全的钥匙 》

回答问题12：心血管回顾性研究采用mace作为结局哪些地方会被挑战？

 

欢迎点赞、评论、分享

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1996419, encodeId=c55d19964197b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 25 11:35:20 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656064, encodeId=18301656064df, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun May 01 08:35:20 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575220, encodeId=e6e515e5220ee, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585714, encodeId=829e1585e146b, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003864, encodeId=2d74100386496, content=理学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Fri Jul 30 14:12:15 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2022-06-25 yb6560

    #MAC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1996419, encodeId=c55d19964197b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 25 11:35:20 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656064, encodeId=18301656064df, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun May 01 08:35:20 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575220, encodeId=e6e515e5220ee, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585714, encodeId=829e1585e146b, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003864, encodeId=2d74100386496, content=理学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Fri Jul 30 14:12:15 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2022-05-01 shanyongle

    #ACE#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1996419, encodeId=c55d19964197b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 25 11:35:20 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656064, encodeId=18301656064df, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun May 01 08:35:20 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575220, encodeId=e6e515e5220ee, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585714, encodeId=829e1585e146b, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003864, encodeId=2d74100386496, content=理学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Fri Jul 30 14:12:15 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-07-31 lfyang

    #MACE#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1996419, encodeId=c55d19964197b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 25 11:35:20 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656064, encodeId=18301656064df, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun May 01 08:35:20 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575220, encodeId=e6e515e5220ee, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585714, encodeId=829e1585e146b, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003864, encodeId=2d74100386496, content=理学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Fri Jul 30 14:12:15 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-07-31 jiyangfei

    #回顾性研究#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1996419, encodeId=c55d19964197b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jun 25 11:35:20 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656064, encodeId=18301656064df, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sun May 01 08:35:20 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575220, encodeId=e6e515e5220ee, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585714, encodeId=829e1585e146b, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Jul 31 00:35:20 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003864, encodeId=2d74100386496, content=理学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Fri Jul 30 14:12:15 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-07-30 ms3000001999514966

    理学知识

    0

相关资讯

除了应用巢式病例对照实验，还有什么方法可以处理非死亡时间偏倚和生存者偏倚？

除了应用巢式病例对照实验，还有其他方法可以处理非死亡时间偏倚和生存者偏倚-第十一个问题

目前国际上有什么前沿的药物流行病学方向？

目前国际上有什么前沿的药物流行病学方向可以分享一下吗？-第六个

处理定量药物暴露的原则

处理定量药物暴露的原则-第七个问题

药物警戒与药物流行病学是什么样的关系？

药物警戒与药物流行病学是什么样的关系？-第五个问题.v

怎样获取数据库？

怎样获取数据库？

除了associated with，还有哪些其他更弱的表示暴露因子和结局的表达方法？

除了associated with，还有哪些其他更弱的表示暴露因子和结局的表达方法？

拓展阅读

JACC：术中低血压增加死亡率？维持较高血压可能并不能减少不良预后！

这些发现并不支持普遍以较高的术中血压为目标来减少术后并发症。

Diabetes Care：非白蛋白尿CKD的2型糖尿病患者肾脏功能快速下降、全因死亡和MACE的风险

由此可见，非白蛋白尿CKD患者的eGFR下降速率比其他任何组均慢。然而，与没有CKD的个体相比，这些人仍然具有更大的死亡和MACE风险。

JAMA：代谢手术可降低糖尿病患者主要心血管事件发生率

对于II型糖尿病以及肥胖人群，接受代谢手术可降低主要心血管事件发生率

2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控

诺和诺德公司近日宣布，PIONEER 6试验通过比较口服semaglutide（胰高血糖素样肽-1类似物）与安慰剂，基于137个首次主要不良心血管事件和16个月的中位随访，证明了semaglutide的主要不良心血管事件（MACE）的非劣性。

JAMA Cardiol：中国急性冠脉综合征（ACS）临床路径研究项目--第三期（CPACS-3）的主要研究结果

近日，JAMA Cardiology在线发表了由北京大学临床研究所常务副所长武阳丰教授和北京阜外医院高润霖院士共同牵头开展的中国急性冠脉综合征（ACS）临床路径研究项目--第三期（CPACS-3）的主要研究结果。该研究通过近3万例患者的大型随机对照试验，证实“以实施临床路径为主的医疗质量改进行动”的干预效果没有达到预期。

Diabetes Care：胰腺和肾脏同步移植患者的主要不良心血管事件

由此可见，该研究报告了SPKT受者MACE的发生率很高。有许多变量可以预测MACE，而非致死性MACE会增加后续同种异体移植失败的风险。来自高血压供体的器官与具有较低心血管风险的受体匹配可能是有益的。移植前心血管风险评分可能有助于确定将从危险因素优化或替代移植疗法中受益的患者，并需要进一步在全国范围内进行验证。